CHLORDIAZEPOXIDE HYDROCHLORIDE

First approved in 1960

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H14ClN3O.ClH
Molecular Weight	336.216
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of CHLORDIAZEPOXIDE HYDROCHLORIDE

Structure Search

SMILES

Cl.CNC1=NC2=C(C=C(Cl)C=C2)C(C3=CC=CC=C3)=[N+]([O-])C1

InChI

InChIKey=DMLFJMQTNDSRFU-UHFFFAOYSA-N

InChI=1S/C16H14ClN3O.ClH/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15;/h2-9H,10H2,1H3,(H,18,19);1H

HIDE SMILES / InChI

Molecular Formula	C16H14ClN3O
Molecular Weight	299.755
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012249s049lbl.pdf
Curator's Comment: description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT00136617 | https://www.drugs.com/pro/chlordiazepoxide.html | https://clinicaltrials.gov/ct2/show/NCT03012815 | https://www.ncbi.nlm.nih.gov/pubmed/6135616 | https://www.ncbi.nlm.nih.gov/pubmed/6304314

Chlordiazepoxide (trade name Librium) is a sedative and hypnotic medication of the benzodiazepine class. Chlordiazepoxide is indicated for the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of Librium in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. Chlordiazepoxide acts on benzodiazepine allosteric sites that are part of the GABAA receptor/ion-channel complex and this results in an increased binding of the inhibitory neurotransmitter GABA to the GABAA receptor thereby producing inhibitory effects on the central nervous system and body similar to the effects of other benzodiazepines. Chlordiazepoxide act via micromolar benzodiazepine binding sites as Ca2+ channel blockers and significantly inhibit depolarization-sensitive Calcium uptake in animal nerve terminal preparations. The withdrawal of chlordiazepoxide during pregnancy and breastfeeding is recommended, as chlordiazepoxide rapidly crosses the placenta and also is excreted in breast milk. Chlordiazepoxide is a long-acting benzodiazepine drug. The half-life of Chlordiazepoxide is 5 – 30 hours but has an active benzodiazepine metabolite (desmethyldiazepam), which has a half-life of 36 – 200 hours. The necessity of discontinuing therapy because of undesirable effects has been rare. Drowsiness, ataxia and confusion have been reported in some patients — particularly the elderly and debilitated. While these effects can be avoided in almost all instances by proper dosage adjustment, they have occasionally been observed at the lower dosage ranges. In a few instances syncope has been reported.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
GABA-A receptor; alpha-1/beta-3/gamma-2 16 Target ID: CHEMBL2094121 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15537339	Positive Allosteric Modulator 178	605.0 nM [Ki]
GABA-A receptor; alpha-2/beta-3/gamma-2 12 Target ID: CHEMBL2094130 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15537339	Positive Allosteric Modulator 178	392.0 nM [Ki]
GABA-A receptor; alpha-3/beta-3/gamma-2 11 Target ID: CHEMBL2094120 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15537339	Positive Allosteric Modulator 178	471.0 nM [Ki]
GABA-A receptor; alpha-5/beta-3/gamma-2 14 Target ID: CHEMBL2094122 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15537339	Positive Allosteric Modulator 178	368.0 nM [Ki]
GABA-A receptor; anion channel 197 Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6135616	Positive Allosteric Modulator 178

Conditions

Condition	Modality	Highest Phase	Product
Anxiety 266 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012249s049lbl.pdf	Primary	Approved 8307	LIBRELEASE Approved Use Chlordiazepoxide HCl capsules USP are indicated for the management of anxiety disorders or for the short term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of chlordiazepoxide HCl capsules USP in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. Launch Date 4.32172794E11
Withdrawal symptoms of acute alcoholism 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012249s049lbl.pdf	Primary	Approved 8307	LIBRELEASE Approved Use Chlordiazepoxide HCl capsules USP are indicated for the management of anxiety disorders or for the short term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of chlordiazepoxide HCl capsules USP in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. Launch Date 4.32172794E11
Major depressive disorder 172 Sources: https://clinicaltrials.gov/ct2/show/NCT01109030	Primary	Phase III 651	LIBRELEASE Approved Use Chlordiazepoxide HCl capsules USP are indicated for the management of anxiety disorders or for the short term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of chlordiazepoxide HCl capsules USP in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. Launch Date 4.32172794E11

C_max

Value	Dose	Analyte	Population
0.86 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/359214	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORDIAZEPOXIDE blood	Homo sapiens population: UNKNOWN age: ADULT sex: MALE food status: UNKNOWN
1.65 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/359214	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORDIAZEPOXIDE blood	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.84 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286030	25 mg single, intramuscular dose: 25 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	CHLORDIAZEPOXIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.69 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286030	25 mg single, intramuscular dose: 25 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	CHLORDIAZEPOXIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
7.16 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/770046	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORDIAZEPOXIDE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
26.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286030	25 mg single, intramuscular dose: 25 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	CHLORDIAZEPOXIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
53.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286030	25 mg single, intramuscular dose: 25 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	CHLORDIAZEPOXIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
8.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/770046	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORDIAZEPOXIDE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
16.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286030	25 mg single, intramuscular dose: 25 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	CHLORDIAZEPOXIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
40.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7286030	25 mg single, intramuscular dose: 25 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	CHLORDIAZEPOXIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
95.5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/359214			CHLORDIAZEPOXIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/413145	unhealthy, 24-74 years Health Status: unhealthy Age Group: 24-74 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/413145	Sources: https://pubmed.ncbi.nlm.nih.gov/413145
20 mg 3 times / day multiple, oral Studied dose Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Co-administed with:: opioids Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012249s049lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: Severe Anxiety Disorders Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012249s049lbl.pdf	Disc. AE: Sedation, Coma... AEs leading to discontinuation/dose reduction: Sedation Coma Respiratory depression Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012249s049lbl.pdf

AEs

AE	Significance	Dose	Population
Coma	Disc. AE	20 mg 3 times / day multiple, oral Studied dose Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Co-administed with:: opioids Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012249s049lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: Severe Anxiety Disorders Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012249s049lbl.pdf
Respiratory depression	Disc. AE	20 mg 3 times / day multiple, oral Studied dose Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Co-administed with:: opioids Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012249s049lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: Severe Anxiety Disorders Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012249s049lbl.pdf
Sedation	Disc. AE	20 mg 3 times / day multiple, oral Studied dose Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Co-administed with:: opioids Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012249s049lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: Severe Anxiety Disorders Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012249s049lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1670 inducer 753		substrate 1168 inhibitor 1789

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
Ca2+ channels 41	P-gp 1491 CYP1A2 1013	CYP1A2 671

Drug as perpetrator

Target	Modality	Activity
CYP2D6 1826	inhibitor 3185 Sources: https://www.jstage.jst.go.jp/article/cpb/59/2/59_2_249/_article/-char/ja/ Page: 251.0	likely
CYP1A2 1620	inducer 1515 Sources: https://www.sciencedirect.com/science/article/pii/S0378427410000184?casa_token=tnbKlh7mxs0AAAAA:rpzG86vMq1DWoibDepNBY9FsqNcI_RYU0qRjzYokbv1b1L5jPrgCcywgCpM8wxqUty9BCRiEtg78 Page: abstract	no
CYP3A4 1857	inducer 1515 Sources: https://www.sciencedirect.com/science/article/pii/S0378427410000184?casa_token=tnbKlh7mxs0AAAAA:rpzG86vMq1DWoibDepNBY9FsqNcI_RYU0qRjzYokbv1b1L5jPrgCcywgCpM8wxqUty9BCRiEtg78 Page: abstract	no
Ca2+ channels 44	inhibitor 3185 Sources: https://www.jstage.jst.go.jp/article/jjp/85/4/85_4_339/_article/-char/ja/ Page: 344.0	yes [IC50 300 uM]

Drug as victim

Target	Modality	Activity
CYP2D6 1168	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071297s030lbl.pdf Page: 1.0	likely
CYP3A4 1670	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27317413/ Page: 1476.0	major
CYP1A2 1013	substrate 3264 Sources: https://europepmc.org/article/med/18646550 Page: 311.0	yes
P-gp 1491	substrate 3264 Sources: https://search.proquest.com/openview/de75715c450da33296c5455f6717b9ab/1?pq-origsite=gscholar&cbl=43703 Page: 136.0	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3611	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3611
ZINC	ZINC000019632917	http://zinc15.docking.org/substances/ZINC000019632917
eMolecules	901620	https://www.emolecules.com/cgi-bin/more?vid=901620

PubMed

Title	Date	PubMed
Clinical toxicity of chlordiazepoxide and diazepam in relation to serum albumin concentration: a report from the Boston Collaborative Drug Surveillance Program.	1974 Jul 26	4851053
Differential diagnosis of cimetidine-induced delirium.	1981 Mar	7220787
Effect of benzodiazepines on the central action of narcotic analgesics.	1982	6132369
Antagonism of drug-induced yawning and penile erections in rats.	1986 Mar 18	2872065
Anticonvulsive and convulsive effects of lidocaine: comparison with those of phenytoin, and implications for mechanism of action concepts.	1988 Sep	2905779
Caffeine-induced anxiogenesis: the role of adenosine, benzodiazepine and noradrenergic receptors.	1989 Jan	2543990
Chlordiazepoxide metabolite accumulation in liver disease.	1989 Jan-Feb	2710011
Expression cloning of a cDNA encoding the mouse pituitary thyrotropin-releasing hormone receptor.	1990 Dec	2175902
Prenatal oxazepam enhances mouse maternal aggression in the offspring, without modifying acute chlordiazepoxide effects.	1991 Jan-Feb	1646381
Magnesium valproate attenuates hyperactivity induced by dexamphetamine-chlordiazepoxide mixture in rodents.	1993 Jun 24	8103460
The attenuation of suppression of motility by triazolam in the conditioned fear stress task is exacerbated by ethanol in mice.	1995	7637548
GABA(A) receptor epsilon-subunit may confer benzodiazepine insensitivity to the caudal aspect of the nucleus tractus solitarii of the rat.	2001 Nov 1	11691872
The new antiepileptic drug levetiracetam normalises chlordiazepoxide withdrawal-induced anxiety in mice.	2002 Mar 29	11937098
[Monoaminergic and aminoacidergic mechanisms of the posterior hypothalamus in realization of the antiaversive effects of anxiosedative and anxioselective agents in various anxiety models].	2002 Sep-Oct	12596508
[Determination of diazepine derivatives: alprazolam, medazepam, chlordiazepoxid mixture by high performance liquid chromatography].	2003	14617856
Anxiolytic effects of the novel anti-epileptic drug levetiracetam in the elevated plus-maze test in the rat.	2003 Nov 14	14637176
Chlordiazepoxide interactions with scopolamine and dizocilpine: novel cooperative and antagonistic effects on spatial learning.	2005 Oct	16300439
Protein synthesis and the mechanisms of lasting change in anxiety induced by severe stress.	2006 Feb 28	16256211
Involvement of noradrenergic and corticoid receptors in the consolidation of the lasting anxiogenic effects of predator stress.	2007 May 16	17335916
Pharmacological modulation of stress reactivity dissociates general learning ability from the propensity for exploration.	2007 Oct	17907827
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.	2010 Dec	20829430

Patents

Sample Use Guides

In Vivo Use Guide

Relief of Mild and Moderate Anxiety Disorders and Symptoms of Anxiety: 5 mg or 10 mg, 3 or 4 times daily Relief of Severe Anxiety Disorders and Symptoms of Anxiety: 20 mg or 25 mg, 3 or 4 times daily Geriatric Patients, or in the presence of debilitating disease: 5 mg, 2 to 4 times daily

Route of Administration: Oral

In Vitro Use Guide

Eight concentrations of Chlordiazepoxide were added to tubes containing rat brain membranes and [3H]diazepam at a final concentration of 4 mkM. After incubation at 30 C for 10 min, followed by 4 C for 20 min, reactions were terminated by vacuum filtration through Whatman GF/C glass-fiber filters. Nonspecific binding was determined in the presence of 4 mkM unlabeled diazepam. The IC50 of a compound was that concentration resulting in 50% inhibition of [3H]diazepam binding to the membrane fraction.

Substance Class	Chemical Created by `admin` on `Fri Dec 16 16:26:18 UTC 2022` Edited by `admin` on `Fri Dec 16 16:26:18 UTC 2022`
Record UNII	MFM6K1XWDK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CHLORDIAZEPOXIDE HYDROCHLORIDE

Official Name

English

CHLORDIAZEPOXIDE HYDROCHLORIDE [MI]

Common Name

English

CHLORDIAZEPOXIDE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

LYGEN

Brand Name

English

CHLORDIAZEPOXIDE HYDROCHLORIDE [EP MONOGRAPH]

Common Name

English

CHLORDIAZEPOXIDE HYDROCHLORIDE [MART.]

Common Name

English

CHLORDIAZEPOXIDE HCL

Common Name

English

CHLORDIAZEPOXIDE HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

7-Chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine 4-oxide monohydrochloride

Systematic Name

English

3H-1,4-BENZODIAZEPIN-2-AMINE, 7-CHLORO-N-METHYL-5-PHENYL-, 4-OXIDE, MONOHYDROCHLORIDE

Common Name

English

LIBRIUM

Brand Name

English

CHLORDIAZEPOXIDE HYDROCHLORIDE [JAN]

Common Name

English

RO 5-0690

Code

English

RO-5-0690

Code

English

CHLORDIAZEPOXIDE HYDROCHLORIDE [VANDF]

Common Name

English

CHLORDIAZEPOXIDE HYDROCHLORIDE CIV [USP-RS]

Common Name

English

CHLORDIAZEPOXIDE HYDROCHLORIDE [USAN]

Common Name

English

Chlordiazepoxide hydrochloride [WHO-DD]

Common Name

English

CHLORDIAZEPOXIDE HYDROCHLORIDE [USP-RS]

Common Name

English

A-POXIDE

Brand Name

English

CHLORDIAZACHEL

Brand Name

English

CHLORDIAZEPOXIDE HYDROCHLORIDE CIV

Common Name

English

NSC-115748

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C1012

Created by admin on Fri Dec 16 16:26:19 UTC 2022 , Edited by admin on Fri Dec 16 16:26:19 UTC 2022

EPA PESTICIDE CODE

600092

Created by admin on Fri Dec 16 16:26:19 UTC 2022 , Edited by admin on Fri Dec 16 16:26:19 UTC 2022

Code System Code Type Description

NSC

115748

Created by admin on Fri Dec 16 16:26:19 UTC 2022 , Edited by admin on Fri Dec 16 16:26:19 UTC 2022

PRIMARY

FDA UNII

MFM6K1XWDK

Created by admin on Fri Dec 16 16:26:19 UTC 2022 , Edited by admin on Fri Dec 16 16:26:19 UTC 2022

PRIMARY

EPA CompTox

DTXSID40880060

Created by admin on Fri Dec 16 16:26:19 UTC 2022 , Edited by admin on Fri Dec 16 16:26:19 UTC 2022

PRIMARY

CHEBI

3612

Created by admin on Fri Dec 16 16:26:18 UTC 2022 , Edited by admin on Fri Dec 16 16:26:18 UTC 2022

PRIMARY

ECHA (EC/EINECS)

207-117-8

Created by admin on Fri Dec 16 16:26:19 UTC 2022 , Edited by admin on Fri Dec 16 16:26:19 UTC 2022

PRIMARY

DRUG BANK

DBSALT000632

Created by admin on Fri Dec 16 16:26:18 UTC 2022 , Edited by admin on Fri Dec 16 16:26:18 UTC 2022

PRIMARY

EVMPD

SUB01213MIG

Created by admin on Fri Dec 16 16:26:18 UTC 2022 , Edited by admin on Fri Dec 16 16:26:18 UTC 2022

PRIMARY

DAILYMED

MFM6K1XWDK

Created by admin on Fri Dec 16 16:26:18 UTC 2022 , Edited by admin on Fri Dec 16 16:26:18 UTC 2022

PRIMARY

MERCK INDEX

M3355

Created by admin on Fri Dec 16 16:26:19 UTC 2022 , Edited by admin on Fri Dec 16 16:26:19 UTC 2022

PRIMARY

Merck Index

ChEMBL

CHEMBL451

Created by admin on Fri Dec 16 16:26:18 UTC 2022 , Edited by admin on Fri Dec 16 16:26:18 UTC 2022

PRIMARY

NCI_THESAURUS

C47973

Created by admin on Fri Dec 16 16:26:19 UTC 2022 , Edited by admin on Fri Dec 16 16:26:19 UTC 2022

PRIMARY

CAS

438-41-5

Created by admin on Fri Dec 16 16:26:18 UTC 2022 , Edited by admin on Fri Dec 16 16:26:18 UTC 2022

PRIMARY

RXCUI

203173

Created by admin on Fri Dec 16 16:26:19 UTC 2022 , Edited by admin on Fri Dec 16 16:26:19 UTC 2022

PRIMARY

RxNorm

RS_ITEM_NUM

1110009

Created by admin on Fri Dec 16 16:26:19 UTC 2022 , Edited by admin on Fri Dec 16 16:26:19 UTC 2022

PRIMARY

Related Record Type Details


					MFM6K1XWDK

CHLORDIAZEPOXIDE HYDROCHLORIDE

BASIS OF STRENGTH->SUBSTANCE

Interaction Type:

ASSAY (HPLC)

Qualification:

USP

Amount:


					6RZ6XEZ3CR

CHLORDIAZEPOXIDE

PARENT -> SALT/SOLVATE


					MFM6K1XWDK

CHLORDIAZEPOXIDE HYDROCHLORIDE

BASIS OF STRENGTH->SUBSTANCE

Interaction Type:

ASSAY (TITRATION)

Qualification:

EP

Amount:

Related Record Type Details


					FR80014ZBT

OXAZEPAM BENZOPHENONE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					QNG87K5614

6-CHLORO-2-(CHLOROMETHYL)-4-PHENYLQUINAZOLINE 3-OXIDE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					5H9HHL6D74

2?-Benzoyl-2,2,4?-trichloroacetanilide oxime, E-

IMPURITY -> PARENT

Amount:


					8X1XP5M0SB

DEMOXEPAM

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:

Related Record Type Details


					6RZ6XEZ3CR

CHLORDIAZEPOXIDE

ACTIVE MOIETY

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound

Drug as perpetrator